Ovarian clear cell carcinoma, outcomes by stage: The MSK experience Journal Article
| Authors: | Shu, C. A.; Zhou, Q.; Jotwani, A. R.; Iasonos, A.; Leitao, M. M. Jr; Konner, J. A.; Aghajanian, C. A. |
| Article Title: | Ovarian clear cell carcinoma, outcomes by stage: The MSK experience |
| Abstract: | Objective Ovarian clear cell carcinomas (OCCCs) are rare, and uncertainty exists as to the optimal treatment paradigm and validity of the FIGO staging system, especially in early-stage disease. Methods We performed a retrospective cohort study of all OCCC patients diagnosed and treated at Memorial Sloan Kettering Cancer Center between January 1996 and December 2013. Progression-free survival (PFS) and overall survival (OS) were calculated by stage and race, and comparisons were made using the log-rank test. Statistical significance was set at p < 0.05. Type and duration of treatment were also recorded. Results There were 177 evaluable patients. The majority of patients were stage I at diagnosis (110/177, 62.2%). Of these, 60/110 (54.6%) were stage IA, 31/110 (28.2%) were stage IC on the basis of rupture-only, and 19/110 (17.3%) were stage IC on the basis of surface involvement and/or positive cytology of ascites or washings. Patients with stage IA and IC based on rupture-only had similar PFS/OS outcomes. Patients with stage IC based on surface involvement and/or positive cytology had a statistically significant decrement in PFS/OS. Stage was an important indicator of PFS/OS, while race was not. Conclusions OCCC often presents in early stage. Women with stage IA OCCC have excellent prognosis, and future studies should explore whether they benefit from adjuvant chemotherapy. Women with IC OCCC need further staging clarification, as surgical rupture alone affords better prognosis than surface involvement and/or positive cytology. Women with advanced OCCC have poor survival and are often chemotherapy resistant/refractory. New treatment paradigms are needed. © 2015 Elsevier Inc. |
| Keywords: | adult; cancer chemotherapy; cancer survival; aged; major clinical study; overall survival; cisplatin; advanced cancer; ascites; treatment duration; paclitaxel; cancer patient; cancer radiotherapy; cancer staging; outcome assessment; ovarian cancer; carboplatin; progression free survival; multiple cycle treatment; cohort analysis; retrospective study; cancer center; ovary carcinoma; clear cell carcinoma; cytopathology; ovarian clear cell carcinoma; race; progression-free survival; clear cell; cancer prognosis; human; female; priority journal; article; figo staging |
| Journal Title: | Gynecologic Oncology |
| Volume: | 139 |
| Issue: | 2 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-11-01 |
| Start Page: | 236 |
| End Page: | 241 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2015.09.016 |
| PROVIDER: | scopus |
| PUBMED: | 26404183 |
| PMCID: | PMC4632203 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 February 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work